Results 201 to 210 of about 40,685 (224)

Do PCSK9 Inhibitors Impair Memory? A Dual Approach Combining Real-World Data and Genetic Evidence [PDF]

Xuezhong Shi, Shijia Wang, Yongli Yang, Xudong Xia, Jingwen Fan, Jingjing Wang, Nana Wang, Xiaocan Jia   +7 more
openalex   +1 more source

Mendelian randomization analysis of lipid-lowering drug targets and neuropsychiatric disorders. [PDF]

Medicine (Baltimore)
Peng S, Liu M, Du F, Li K.
europepmc   +1 more source

PCSK9 inhibition ameliorates microplastic-induced endothelial redox imbalance via SIRT6 modulation. [PDF]

Cell Mol Biol Lett
D'Onofrio N, Donisi I, Del Vecchio V, Prattichizzo F, Pellegrini V, Barbieri M, Ceriello A, Marfella R, Paolisso G, Balestrieri ML.   +9 more
europepmc   +1 more source

Early PCSK9 Inhibitor Therapy Following Percutaneous Coronary Intervention (PERFECT): A Pilot Randomized Controlled Trial

Jiachun Xia, Zhengguang Xiao, Luyao Wu, Haiyang Yu, Yanan Pang, Shan Hu, Lei Hou   +6 more
openalex   +1 more source

Ribofuranose-based GalNAc-conjugated siRNA enhances the liver-targeted delivery and elicits robust RNAi-mediated gene silencing. [PDF]

Mol Ther Nucleic Acids
Huang ZA, Li ZM, Wang J, Ji GS, Gao ZC, Chen AF, Tian ZK, Yu F, Song GS.   +8 more
europepmc   +1 more source

PCSK9 as a new player in intermittent hypoxia-induced vascular alterations

Marc-Adrien Reveyaz, Alejandro Arco-Hierves, Antoine Boutin-Paradis, Renaud Tamisier, Sébastien Bailly, Van Ngo, Jean‐Louis Pépin, Anne Briançon‐Marjollet   +7 more
openalex   +1 more source

Profiles of PCSK9, SREBP-2, and histopathology in COVID-19 and non-COVID-19 critical illness. [PDF]

BMC Infect Dis
Weber F, Pavel V, Müller M, Boor P, Läber L, von Stillfried S, Buechler C.   +6 more
europepmc   +1 more source

Novel Hypolipidemic Agents: Focus on PCSK9 Inhibitors

, 2013
Antonis S. Manolis, Theodora A. Manolis, Helen Melita   +2 more
openalex   +2 more sources

2025 Egyptian guidelines for the management of dyslipidemia. [PDF]

Egypt Heart J
Reda A, Taha HS, Badran HM, Khamis H, Kamal S, Elserafy AS, Dawoud MH, Elamragy AA, Bendary A, Shaker MM.   +9 more
europepmc   +1 more source

Inclisiran in Dyslipidemia with High Residual Platelet Reactivity. [PDF]

Diseases
Kapsultanova D, Zhangelova S, Nurmukhammad F, Makasheva Z, Sakhov O, Galkina T, Rustamova F, Akhmentayeva D, Aubakirova B.   +8 more
europepmc   +1 more source